What is the appropriate evaluation and management for a male patient with simultaneous elevations in testosterone and estrogen levels?

Elevated Testosterone and Estrogen in Males: Evaluation and Management

A male with simultaneously elevated testosterone and estrogen levels requires immediate investigation to determine if he is on exogenous testosterone therapy, as this is the most common cause of concurrent elevations; if confirmed, management focuses on measuring serum estradiol levels and considering aromatase inhibitor therapy (anastrozole 0.5 mg three times weekly) only if estradiol exceeds 60 pg/mL or is 40-60 pg/mL with symptoms like gynecomastia or breast tenderness.

Initial Diagnostic Approach

The first critical step is determining whether the patient is receiving testosterone therapy, as exogenous testosterone commonly aromatizes to estradiol, particularly in adipose tissue 1, 2. This represents the most frequent scenario for concurrent elevations.

Key History Elements to Obtain:

• Current or recent testosterone replacement therapy (any formulation: injectable, topical gel, patches, pellets)
• Symptoms of hyperestrogenism: gynecomastia, breast tenderness, nipple sensitivity, or breast pain
• Symptoms suggesting other pathology: visual field defects (bitemporal hemianopsia), anosmia, headaches
• Use of anabolic steroids or performance-enhancing substances
• Medications that may affect hormone metabolism

Essential Laboratory Evaluation:

Measure serum estradiol in all cases 3. The 2018 AUA guideline specifically recommends measuring serum estradiol in testosterone-deficient patients who present with breast symptoms or gynecomastia prior to commencing testosterone therapy 3.

Measure serum luteinizing hormone (LH) 3. This helps establish the etiology:

• Low or low-normal LH with elevated testosterone/estrogen suggests exogenous testosterone use or a testosterone-secreting tumor
• Elevated LH would be inconsistent with primary hypergonadism and warrants further investigation

If LH is low or low-normal, measure serum prolactin 3. Persistently elevated prolactin requires endocrinology referral and pituitary imaging to evaluate for prolactinoma or non-secreting adenomas 3.

Management Algorithm

If Patient is ON Testosterone Therapy:

Step 1: Assess Estradiol Levels and Symptoms

The threshold for intervention varies based on symptoms 1, 4:

• Estradiol >60 pg/mL regardless of symptoms: Consider aromatase inhibitor therapy
• Estradiol 40-60 pg/mL WITH symptoms (gynecomastia, breast pain/tenderness): Consider aromatase inhibitor therapy
• Estradiol <40 pg/mL or 40-60 pg/mL without symptoms: Monitor without intervention

Important caveat: Current evidence does not support treating elevated estrogen levels during testosterone therapy in asymptomatic patients, as naturally occurring estrogen elevations may help maintain some aspects of male sexual function 5. Approximately 20% of men on testosterone therapy develop elevated estradiol levels 2.

Step 2: Aromatase Inhibitor Therapy (If Indicated)

Anastrozole 0.5 mg three times weekly is the most commonly prescribed regimen 1, 4. This approach effectively reduces estradiol levels from a median of 65 pg/mL to 22 pg/mL without affecting testosterone levels (which remain stable at approximately 600 ng/dL) 1.

Monitor response at 3-6 months with repeat estradiol and testosterone levels 6. Ensure testosterone levels remain in the mid-normal range while estradiol normalizes.

Critical monitoring point: Some patients develop breast symptoms that spontaneously resolve with continued observation, so a period of watchful waiting based on clinical judgment is reasonable before initiating aromatase inhibitors 3.

If Patient is NOT on Testosterone Therapy:

This scenario requires urgent endocrinology referral to evaluate for:

• Testosterone-secreting tumors (testicular or adrenal)
• Estrogen-secreting tumors
• Aromatase excess syndrome
• Exogenous steroid abuse (patient may not disclose)

Immediate workup includes:

• Testicular examination for masses
• Imaging: testicular ultrasound and adrenal CT/MRI as indicated
• If LH is low/normal with high prolactin: pituitary MRI 3
• Men with total testosterone <150 ng/dL combined with low/normal LH should undergo pituitary MRI regardless of prolactin levels 3

Common Pitfalls to Avoid

1. Do not routinely treat elevated estradiol in asymptomatic men on testosterone therapy. Evidence suggests estrogens may contribute to maintaining sexual function, and treatment lacks proven benefit in the absence of symptoms 5.

2. Avoid prophylactic aromatase inhibitor use. Only 14.4% of practitioners prescribe aromatase inhibitors prophylactically, and this practice lacks evidence support 4.

3. Do not assume elevated estrogen causes low testosterone. In men not on testosterone therapy, naturally occurring estrogen elevations do not appear to cause testosterone deficiency 5.

4. Recognize formulation differences: Injectable testosterone is associated with higher rates of estradiol elevation compared to topical formulations (38.6% vs 34.1% requiring aromatase inhibitors) 1.

5. Monitor for aromatase inhibitor over-treatment: Excessive estrogen suppression may be harmful, as estrogens play physiological roles in male bone health and sexual function 7, 5.

Monitoring Parameters

For patients on testosterone therapy with or without aromatase inhibitors 6:

• Testosterone and estradiol levels: 3-6 months after any intervention, then every 6-12 months
• Hematocrit: Baseline, 3-6 months, then annually (stop therapy if >54%)
• PSA and digital rectal exam: Per age-appropriate screening guidelines
• Clinical assessment: Symptom response and adverse effects at each visit

6, 3, 1, 4, 2, 5